Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial hypertension using AOS™ dry powder inhaler device

被引:8
作者
Sahay, Sandeep [1 ]
Holy, Royanne [2 ]
Lyons, Shirley [3 ]
Parsley, Edwin [3 ]
Maurer, Mari [3 ]
Weers, Jeffry [3 ]
机构
[1] Houston Methodist Hosp, Houston Methodist Lung Ctr, Houston, TX 77030 USA
[2] Houston Methodist Res Inst, Houston, TX USA
[3] Respira Therapeut Inc, Burlingame, CA USA
关键词
pulmonary arterial hypertension; inspiratory flow profiles; inhaled therapies; dry powder inhalers; THERAPY; LIFE;
D O I
10.1177/2045894020985345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Relative to healthy subjects, patients with pulmonary arterial hypertension often present with decreased respiratory muscle strength, resulting in decreased maximum inspiratory pressure. Little is known about the impact of reduced respiratory muscle strength on the ability to achieve the peak inspiratory pressures needed for effective drug delivery when using portable dry powder inhalers (>= 1.0 kPa). The objective of this study was to assess the impact of inhaler resistance and patient instruction on the inspiratory flow profiles of pulmonary arterial hypertension patients when using breath-actuated dry powder inhalers. The inspiratory flow profiles of 35 patients with pulmonary arterial hypertension were measured with variants of the RS01 dry powder inhaler. Profiles were determined with a custom inspiratory flow profile recorder. Results showed that going from the low resistance RS01 dry powder inhaler to the high resistance AOS (R) dry powder inhaler led to increases in mean peak inspiratory pressures for pulmonary arterial hypertension subjects from 3.7 kPa to 6.5 kPa. Instructions that ask pulmonary arterial hypertension subjects to inhale with maximal effort until their lungs are full led to a mean peak inspiratory pressures of 6.0 kPa versus 2.1 kPa when the same subjects are asked to inhale comfortably. Significant decreases in mean peak inspiratory pressures are also observed with decreases in lung function, with a mean peak inspiratory pressures of 7.2 kPa for subjects with FEV1 > 60% predicted, versus 3.3 kPa for those subjects with FEV1 < 50% predicted. In conclusion, despite having reduced respiratory muscle strength, subjects with pulmonary arterial hypertension can effectively use a breath-actuated dry powder inhaler. The probability of achieving effective dose delivery may be increased by using dry powder inhalers with increased device resistance, particularly when subjects do not follow the prescribed instructions and inhale comfortably.
引用
收藏
页数:9
相关论文
共 24 条
  • [1] Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial
    Altman, Pablo
    Wehbe, Luis
    Dederichs, Juergen
    Guerin, Tadhg
    Ament, Brian
    Moronta, Miguel Cardenas
    Valeria Pino, Andrea
    Goyal, Pankaj
    [J]. BMC PULMONARY MEDICINE, 2018, 18
  • [2] The Inhalation Characteristics of Patients When They Use Different Dry Powder Inhalers
    Azouz, Wahida
    Chetcuti, Philip
    Hosker, Harold S. R.
    Saralaya, Dinesh
    Stephenson, John
    Chrystyn, Henry
    [J]. JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2015, 28 (01) : 35 - 42
  • [3] Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
    Chen, Hubert
    Rosenzweig, Erika B.
    Gotzkowsky, S. Karl
    Arneson, Carl
    Nelsen, Andrew C.
    Bourge, Robert C.
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
  • [4] The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates
    Clark, Andrew R.
    Weers, Jeffry G.
    Dhand, Rajiv
    [J]. JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2020, 33 (01) : 1 - 11
  • [5] The Role of Inspiratory Pressures in Determining the Flow Rates Though Dry Powder Inhalers; A Review
    Clark, Andrew R.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (27) : 3974 - 3983
  • [6] STATIC VOLUME-PRESSURE CHARACTERISTICS OF RESPIRATORY SYSTEM DURING MAXIMAL EFFORTS
    COOK, CD
    MEAD, J
    ORZALESI, MM
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1964, 19 (05) : 1016 - &
  • [7] Mechanisms of disease: Pulmonary arterial hypertension
    Farber, HW
    Loscalzo, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (16) : 1655 - 1665
  • [8] The Pharmacological Treatment of Pulmonary Arterial Hypertension
    Frumkin, Lyn R.
    [J]. PHARMACOLOGICAL REVIEWS, 2012, 64 (03) : 583 - 620
  • [9] 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
    Galie, Nazzareno
    Humbert, Marc
    Vachiery, Jean-Luc
    Gibbs, Simon
    Lang, Irene
    Torbicki, Adam
    Simonneau, Gerald
    Peacock, Andrew
    Noordegraaf, Anton Vonk
    Beghetti, Maurice
    Ghofrani, Ardeschir
    Gomez Sanchez, Miguel Angel
    Hansmann, Georg
    Klepetko, Walter
    Lancellotti, Patrizio
    Matucci, Marco
    McDonagh, Theresa
    Pierard, Luc A.
    Trindade, Pedro T.
    Zompatori, Maurizio
    Hoeper, Marius
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (01) : 67 - +
  • [10] Drug therapy: Treatment of pulmonary arterial hypertension
    Humbert, M
    Sitbon, O
    Simonneau, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (14) : 1425 - 1436